{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T21:40:16Z","timestamp":1734730816095,"version":"3.32.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1990,1,1]],"date-time":"1990-01-01T00:00:00Z","timestamp":631152000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1990]]},"DOI":"10.1007\/bf00689272","type":"journal-article","created":{"date-parts":[[2004,11,29]],"date-time":"2004-11-29T16:26:27Z","timestamp":1101745587000},"page":"27-32","source":"Crossref","is-referenced-by-count":6,"title":["Flavone acetic acid and plasma protein binding"],"prefix":"10.1007","volume":"27","author":[{"given":"Joanne","family":"Brodfuehrer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"Valeriote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kam","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance","family":"Heilbrun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Corbett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/bjc.1987.32","volume":"55","author":"MC Bibby","year":"1987","unstructured":"Bibby MC, Double JA, Phillips RM, Loadman PM (1987) Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). Br J Cancer 55: 159","journal-title":"Br J Cancer"},{"key":"CR2","first-page":"1279","volume":"48","author":"M-C Bissery","year":"1988","unstructured":"Bissery M-C, Valeriote FA, Chabot GC, Crissman JD, Yost C, Corbett TH (1988) Flavone acetic acid (NSC-347 512) induced DNA damage in Glasgow osteogenic sarcoma in vivo. Cancer Res 48: 1279","journal-title":"Cancer Res"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/0277-5379(87)90096-4","volume":"23","author":"LS Capolongo","year":"1987","unstructured":"Capolongo LS, Balconi G, Ubezio P, Giavazzi R, Taraboletti G, Regonesi A, Yoder OC, D'Incalci M (1987) Antiproliferative properties of flavone acetic acid (NSC 347 512) (LM975), a new anti-cancer agent. Eur J Cancer Clin Oncol 23: 1529","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF00435845","volume":"23","author":"J Cassidy","year":"1989","unstructured":"Cassidy J, Kerr DJ, Setanoians A, Zaharko DS, Kaye SB (1989) Could interspecies differences in the protein binding of flavone acetic acid contribute to the failure to predict lack of efficacy in patients? Cancer Chemother Pharmacol 23: 397","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/0277-5379(87)90357-9","volume":"23","author":"L-M Ching","year":"1987","unstructured":"Ching L-M, Baguley BC (1987) Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512). Eur J Cancer Clin Oncol 23: 1047","journal-title":"Eur J Cancer Clin Oncol"},{"volume-title":"Plant flavonoids in biology and medicine: biochemical, pharmacological, and structure-activity relationships","year":"1986","key":"CR6","unstructured":"Cody V, Middleton E Jr, Harborne JB (eds) (1986) Plant flavonoids in biology and medicine: biochemical, pharmacological, and structure-activity relationships. Alan Liss, New York"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/00031305.1981.10479327","volume":"35","author":"WJ Conover","year":"1981","unstructured":"Conover WJ, Iman RL (1981) Rank transformations as a bridge between parametric and nonparametric statistics. Am Stat 35: 124","journal-title":"Am Stat"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00179586","volume":"4","author":"TH Corbett","year":"1986","unstructured":"Corbett TH, Bissery M-C, Wozniak A, Plowman J, Polin L, Tapazoglou E, Dieckman J, Valeriote F (1986) Activity of flavone acetic acid (NSC-347 512) against solid tumors of mice. Invest New Drugs 4: 207","journal-title":"Invest New Drugs"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF00304756","volume":"24","author":"J Cummings","year":"1989","unstructured":"Cummings J, Smyth JF (1989) Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours. Cancer Chemother Pharmacol 24: 269","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR10","first-page":"3587","volume":"49","author":"J Cummings","year":"1989","unstructured":"Cummings J, Double JA, Bibby MC, Farmer P, Evans S, Kerr DJ, Kaye SB, Smyth JF (1989) Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice. Cancer Res 49: 3587","journal-title":"Cancer Res"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/B978-0-12-609107-6.50022-2","volume":"7","author":"BT Doumas","year":"1972","unstructured":"Doumas BT, Biggs HG (1972) Determination of serum albumin. Stand Methods Clin Chem 7: 175","journal-title":"Stand Methods Clin Chem"},{"key":"CR12","first-page":"4749","volume":"48","author":"JL Evelhoch","year":"1988","unstructured":"Evelhoch JL, Bissery M-C, Chabot GG, McCoy CL, Simpson NE, Heilbrun LK, Corbett TH (1988) Flavone acetic acid (NSC-347 512)-induced modification of tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res 48: 4749","journal-title":"Cancer Res"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0006-2952(81)90151-9","volume":"7","author":"KJ Fehske","year":"1981","unstructured":"Fehske KJ, Muller WE, Woller U (1981) The location of drug binding sites in human serum albumin. Biochem Pharmacol 7: 687","journal-title":"Biochem Pharmacol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0003-2697(72)90084-X","volume":"48","author":"HA Feldman","year":"1972","unstructured":"Feldman HA (1972) Mathematical theory of complex ligand-binding systems at equilibrium: some methods for parameter fitting. Anal Biochem 48: 317","journal-title":"Anal Biochem"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/jnci\/80.4.241","volume":"80","author":"GJ Finlay","year":"1988","unstructured":"Finlay GJ, Smith GP, Fray LM, Baguley BC (1988) Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect. J Natl Cancer Inst 80: 241","journal-title":"J Natl Cancer Inst"},{"key":"CR16","volume-title":"Statistical analysis system (SAS) for linear models. Report 55, NC","author":"RJ Freund","year":"1986","unstructured":"Freund RJ, Littel RC (1986) Statistical analysis system (SAS) for linear models. Report 55, NC: SAS Institute, Bethesda, Maryland"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/BF00257307","volume":"22","author":"A Gouyette","year":"1988","unstructured":"Gouyette A, Kerr DJ, Kaye SB, Setanoians A, Casside J, Bradley C, Forrest G, Soukpo M (1988) Flavone acetic acid: a nonlinear pharmacokinetic model. Cancer Chemother Pharmacol 22: 114","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/0006-2952(83)90262-9","volume":"32","author":"B Havsteen","year":"1983","unstructured":"Havsteen B (1983) Commentary: flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol 32: 1141","journal-title":"Biochem Pharmacol"},{"key":"CR19","first-page":"17","volume":"33","author":"U Kragh-Hansen","year":"1981","unstructured":"Kragh-Hansen U (1981) Molecular aspects of ligand binding to serum albumin. Pharmacol Rev 33: 17","journal-title":"Pharmacol Rev"},{"key":"CR20","volume-title":"Clinical brochure: flavone acetic acid, NSC-347 512","author":"National Cancer Institute","year":"1985","unstructured":"National Cancer Institute (1985) Clinical brochure: flavone acetic acid, NSC-347 512. NCI, Bethesda, Maryland"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2141.1956.tb06681.x","volume":"2","author":"RA Neely","year":"1956","unstructured":"Neely RA, Neil DW (1956) Electrophoretic studies on the serum proteins in neoplastic disease involving the haemopoietic and reticuloendothelial system. Br J Haematol 2: 32","journal-title":"Br J Haematol"},{"key":"CR22","first-page":"631","volume":"70","author":"J Plowman","year":"1986","unstructured":"Plowman J, Narayanan VL, Dykes D, Szarvasi E, Briet P, Yoder OC, Paull KD (1986) Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep 70: 631","journal-title":"Cancer Treat Rep"},{"key":"CR23","first-page":"624","volume":"33","author":"A Rotfino","year":"1948","unstructured":"Rotfino A, Suchoff D, Stein KG (1948) Electrophoretic study of the blood serum from lymphogranulomatous patients. J Lab Clin Med 33: 624","journal-title":"J Lab Clin Med"},{"key":"CR24","first-page":"188","volume":"29","author":"AE Staubus","year":"1988","unstructured":"Staubus AE, Grever MR, Malspeis L (1988) Plasma protein binding of flavone acetic acid (FAA) during continuous intravenous infusion to cancer patients. Proc Am Assoc Cancer Res 29: 188","journal-title":"Proc Am Assoc Cancer Res"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/1097-0142(196009\/10)13:5<974::AID-CNCR2820130519>3.0.CO;2-Y","volume":"13","author":"JL Steinfeld","year":"1960","unstructured":"Steinfeld JL (1960) [131I]-Albumin degradation in patients with neoplastic disease. Cancer 13: 974","journal-title":"Cancer"},{"key":"CR26","first-page":"1052","volume":"12","author":"G Sudlow","year":"1976","unstructured":"Sudlow G, Birkett DJ, Wade DN (1976) Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol 12: 1052","journal-title":"Mol Pharmacol"},{"key":"CR27","first-page":"98","volume":"13","author":"JM Thorp","year":"1972","unstructured":"Thorp JM (1972) Inter- and intra-species differences in the binding of anionic compounds to albumin. Proc Eur Soc Study Drug Tox 13: 98","journal-title":"Proc Eur Soc Study Drug Tox"},{"key":"CR28","first-page":"312","volume":"28","author":"MW Trader","year":"1987","unstructured":"Trader MW, Harrison SD Jr, Laster WR Jr, Griswold DP Jr (1987) Cross-resistance and collateral sensitivity of drug-resistant P388 and L1210 leukemias to flavone acetic acid (FAA, NSC 347 512) in vivo. Proc Am Assoc Cancer Res 28: 312","journal-title":"Proc Am Assoc Cancer Res"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1172\/JCI104703","volume":"42","author":"T Waldman","year":"1962","unstructured":"Waldman T, Trier J, Fallon H (1962) Albumin metabolism in patients with lymphoma. J Clin Invest 42: 171","journal-title":"J Clin Invest"},{"key":"CR30","first-page":"5878","volume":"48","author":"RB Weiss","year":"1988","unstructured":"Weiss RB, Greene RF, Knight RD, Collins JM, Pelosi JJ, Sulkes A, Curt GA (1988) Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347 512). Cancer Res 48: 5878","journal-title":"Cancer Res"},{"key":"CR31","first-page":"1415","volume":"70","author":"DS Zaharko","year":"1986","unstructured":"Zaharko DS, Grieshaber CK, Plowman J, Craddock JC (1986) Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumours. Cancer Treat Rep 70: 1415","journal-title":"Cancer Treat Rep"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00689272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00689272\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00689272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T21:03:54Z","timestamp":1734728634000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00689272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1990]]}},"alternative-id":["BF00689272"],"URL":"https:\/\/doi.org\/10.1007\/bf00689272","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[1990]]}}}